Fulltext

Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus

Veloso, Tiago Rafael ; Oechslin, Frank ; Que, Yok-Ai ; Moreillon, Philippe ; Entenza, José Manuel ; Mancini, Stefano ; Oswald, Eric

In: Pathogens and Disease, 2015, vol. 73, no. 8, p. -

Zum persönliche Liste hinzufügen
    Titel
    • Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus
    Autor
    • Veloso, Tiago Rafael. Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland
    • Oechslin, Frank. Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland
    • Que, Yok-Ai. Department of Intensive Care Medicine, Lausanne University Hospital Center (CHUV), CH-1011 Lausanne, Switzerland
    • Moreillon, Philippe. Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland
    • Entenza, José Manuel. Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland
    • Mancini, Stefano. Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland
    • Oswald, Eric
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Pathogens and Disease, 2015, vol. 73, p. 8. Oxford University Press
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:294274
    Summary
    Enterococcus faecalis and Streptococcus gallolyticus cause infective endocarditis (IE), which can originate from the continuous release or translocation of low bacterial numbers into the bloodstream. In this context, IE cannot be prevented with antibiotics. We previously demonstrated that aspirin plus ticlopidine protected rats from IE due to S. gordonii and Staphylococcus aureus. Here we showed that aspirin plus ticlopidine significantly reduced vegetation weight and protected 73 and 64% rats (P < 0.005) from IE due to E. faecalis and S. gallolyticus, respectively. These results further support the potential use of aspirin plus ticlopidine for a global prevention of IE in high-risk patients